Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/dZpBCduTtWCfcQwXCidncVCicNRWQv
| Positive FSD Trial Results Push Palatin Shares Higher | | In the world of biotech's binary events where a company's stock price can swing wildly in value on the announcement of clinical results, good news always swings the needle in the positive direction. That is certainly the case with Palatin Technologies Inc., after reporting positive top-line results from its phase IIb trial on bremelanotide. Find out the details. |  |
| Health Care & Policy |  |  | | - Firms eye development of targeted cancer drugs
AstraZeneca has teamed up with Foundation Medicine to identify genetic mutations in cancer-related tumor genes that may help predict a person's response or resistance to targeted treatments. Under terms of the deal, Foundation will get right of first negotiation to develop diagnostic tests. The deal will allow AstraZeneca to "identify tumor-specific defects and alterations that can be used for patient segmentation," said Susan Galbraith, vice president and head of AstraZeneca's Oncology Innovative Medicines Unit. GenomeWeb Daily News (free registration) (11/12)       - Novartis' Ilaris hits primary goals in 2 rare disease trials
Novartis said its interleukin-1 beta inhibitor Ilaris, or ACZ885, met both the main goals of two separate midstage studies involving patients with the genetic diseases familial Mediterranean fever and TRAPS. Ilaris reduced attack frequency by 50% in FMF patients, and the drug relieved TRAPS patients' symptoms for an average of three months. Reuters (11/11) - Gilead reports promising findings for combined hepatitis C therapy
Gilead Sciences reported at a liver disease meeting that the combination of hepatitis C drugs sofosbuvir, ribavirin and GS-5885 resulted in a 100% cure rate in patients with genotype 1 chronic hepatitis C virus. Virus infection was at undetectable levels four weeks following the combined therapy in all 25 patients involved in the trial, the company said. Reuters (11/10) - Researchers say heart cells may work as "biological pacemaker"
Researchers at the Technion-Israel Institute of Technology said they have created working heart muscles from patients' stem cells and skin cells. Researchers said the cells could function as a "biological pacemaker" to correct irregular or slow heartbeats. "We found that the electrical signal from the heart cells we created synchronized the beat of any surrounding heart tissue," researcher Dr. Oren Caspi said. Researchers are collaborating with heart specialists to move toward clinical trials. The Telegraph (London) (tiered subscription model) (11/11) | Company & Financial News | | | | - Vital raises funds to advance bio-artificial liver to Phase III trials
A regulatory filing disclosed that Vital Therapies has gained $86.1 million since September, bringing the company's total fundraising to about $150 million. The company announced in September that the money will allow it to move its Elad bio-artificial liver to three pivotal Phase III trials in 375 patients with fulminant hepatic failure and acute alcoholic hepatitis. MedCityNews.com (11/9) | Global Developments | | | | - Synthetic biology studies win $31.8M grants from U.K.
The U.K. government awarded grants totaling $31.8 million to six research projects that seek to use synthetic biology-based methods to address major global challenges such as cutting carbon emissions and reducing the price of agrochemical production. The funding program is part of the government's efforts to make the U.K. a global leader in synthetic biology-based businesses. Grant recipients include the University of Nottingham, the University of Exeter and the John Innes Centre. GenomeWeb Daily News (free registration) (11/12) | Food & Agriculture | | | | - Why Canada should not ban biotech food ingredients
 Prohibiting the use of biotech ingredients in food products in Canada would drive up the grocery bill of average consumers by as much as $400 per year, writes Sylvain Charlebois, the University of Guelph's associate dean for management and economics. Biotech food products have been shown to be safe for human consumption, and consumer comfort with biotechnology is likely to grow, Charlebois writes. The Record (Kitchener, Ontario) (11/13) | Industrial & Environmental | | | | | News from BIO | | | | - Ship with FedEx
FedEx is now offering member companies discounts of up to 35% off select FedEx services, both U.S. and international services. The BIO program with FedEx is one of the many cost-savings programs offered by BIO through its Business Solutions program. There is no charge for BIO member companies to participate in any of the BIO Business Solutions programs -- it is a benefit of membership. Learn more about the BIO and FedEx program.
| SmartQuote | | | |  | For the happiest life, rigorously plan your days, leave your nights open to chance."
--Mignon McLaughlin,
American author and journalist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, November 12, 2012
- Friday, November 09, 2012
- Thursday, November 08, 2012
- Wednesday, November 07, 2012
- Tuesday, November 06, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment